Fierce Biotech

Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'

Roche is plugging 710 billion won (about $484 million) into South Korea’s biopharma industry, with the goal of attracting ...
Fierce Biotech

UK invests $64M to expand clinical trial access to underserved communities

In an effort to boost global biopharma competitiveness, the U.K.’s National Institute for Health and Care Research (NIHR) has ...
Fierce Biotech

Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...
Fierce Biotech

Nvidia dives deeper into medtech, cancer research with Droplet Biosciences

Nvidia, the computer chip giant, continues its deep dive into expanding artificial intelligence technology in the medtech and cancer research arenas, this time with diagnostics maker Droplet ...
Fierce Biotech

Bayer tosses one Pompe gene therapy from $2B AskBio buyout to focus on alternative option

Bayer has discontinued an early-stage clinical gene therapy for a rare genetic disorder in favor of a similar candidate. | Bayer has discontinued an early-stage clinical gene therapy for a rare ...
Fierce Biotech

Teva bags $400M deal with Blackstone to fund Sanofi-partnered IBD drug

Two weeks after Teva touted promising long-term data for its Sanofi-partnered bowel disease drug, the Israeli pharma ...
Fierce Biotech

UCB enters TCE space with $1.1B deal for Chinese biotech's autoimmune candidate

UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate.
Fierce Biotech

RadNet snaps up Gleamer for €215M upfront to bolster its AI imaging portfolio

U.S.-based RadNet is paying 215 million euros upfront, with another 15 million euros on the table tied to future milestones. RadNet plans to merge Gleamer with its 2020 DeepHealth buy, its artificial ...
Fierce Biotech

FDA details rationale for rejecting rare disease gene therapy from Regenxbio

RGX-121 was rejected in early February, with Regenxbio listing the primary reasons given by the FDA as concerns about the ability to properly define a patient population, the use of a natural history ...
Fierce Biotech

AI musculoskeletal imaging medtechs Medimaps and Radiobotics pen merger deal

Medimaps markets AI-driven bone microarchitecture imaging technologies such as TBS Osteo and TBS Reveal, which assess ...
Fierce Biotech

Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug

Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate. | Disc Medicine is laying off a fifth of its workforce as the ...
Fierce Biotech

New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program

Two new cancer cases have prompted Kyowa Kirin to shutter all clinical studies of its investigational anti-OX40 monoclonal antibody designed to treat inflammatory diseases. | Two new cancer cases have ...